Cadrenal Therapeutics (CVKD) Other financing activities (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Other financing activities of $1.4 million for Q1 2026, up 8439.24% sequentially from $16003.0 in Q3 2025, and down 33.52% YoY from $2.1 million in Q1 2025.
Cadrenal Therapeutics (CVKD) Other financing activities (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Other financing activities for 5 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Other financing activities fell 33.52% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$640936.0 (down 131.18% YoY) and the FY2025 annual result came in at $48000.0, up 16007.38% from the prior year.
- Other financing activities grew to $1.4 million in Q1 2026 per CVKD's latest filing, from $16003.0 in the prior quarter.
- Over five years, Other financing activities peaked at $5.2 million in Q2 2023 and troughed at -$5.2 million in Q4 2023.
- A 5-year average of $167278.3 and a median of $11751.5 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2024: Other financing activities jumped 1146250.0% in 2023, then tumbled 99.88% in 2024.
- Over 5 years, Other financing activities stood at $450.0 in 2022, then slumped by 1146450.0% to -$5.2 million in 2023, then surged by 100.01% to $298.0 in 2024, then surged by 5270.13% to $16003.0 in 2025, then surged by 8439.24% to $1.4 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $1.4 million, $16003.0, and -$2.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Mar 31, 2026 | 1.37 Mn |
| Sep 30, 2025 | 16,003.00 |
| Sep 30, 2025 | 16,003.00 |
| Jun 30, 2025 | -2.02 Mn |
| Jun 30, 2025 | -2.02 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2025 | 2.06 Mn |
| Mar 31, 2024 | 298.00 |
| Mar 31, 2024 | 298.00 |
| Dec 31, 2023 | -5.16 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Jun 30, 2023 | 5.16 Mn |
| Jun 30, 2023 | 5.16 Mn |
| Mar 31, 2023 | 250,000.00 |
| Mar 31, 2023 | 250,000.00 |
| Jun 30, 2022 | 450.00 |
| Jun 30, 2022 | 450.00 |